---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-022335"
form_type: "8-K"
ticker: "RLYB"
cik: "0001739410"
company_name: "Rallybio Corp"
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:37:37.672086+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rallybio Q3 net loss widens to $18.4M; positive RLYB116 Phase 1 data with >99% C5 reduction

## Summary
- Net loss $18.4M for Q3 2022, vs $10.2M for Q3 2021; net loss per share $0.60.
- Cash, cash equivalents, and marketable securities $132.4M as of Sep 30, 2022; runway into Q1 2024.
- RLYB212 Phase 1b shows rapid elimination of transfused platelets; proof-of-concept data expected Q1 2023.
- RLYB116 Phase 1: >99% reduction in free C5 within 24 hrs at 100 mg SC; half-life >300 hrs; MAD study in Q1 2023.
- R&D expenses $12.1M (up 142% YoY) driven by RLYB212 and RLYB116 development.

## SEC filing metadata
- accession: 0000950170-22-022335
- form_type: 8-K
- ticker: RLYB
- cik: 0001739410
- company_name: Rallybio Corp
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739410/000095017022022335/0000950170-22-022335-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739410/000095017022022335/rlyb-20221107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-022335
- JSON: https://secwatch.observer/filing/0000950170-22-022335.json
- Plain text: https://secwatch.observer/filing/0000950170-22-022335.txt

## Key facts
- Earnings Releases
  Rallybio Corp reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: On November 7, 2022, Rallybio Corporation issued a press release announcing its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739410/000095017022022335/0000950170-22-022335-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.